Roche AG unit Genentech Inc. said top-line data from a phase III study of Kadcyla (ado-trastuzumab emtansine) failed to beat the standard of care, Herceptin (trastuzumab) and a taxane, in helping people with previously untreated advanced HER2-positive breast cancer live longer without their disease worsening.